MDS Patient Registries - Achievements and Challenges

Overview

Journal Ann Hematol

Specialty Hematology

Date 2024 Aug 22

PMID 39174754

Authors

Tilman Steinmetz

Uwe Totzke

Annika Kasprzak

Stephan Schmitz

Norbert Gattermann

Ulrich Germing

Affiliations

Soon will be listed here.

Abstract

Since the late 1980s, patient registries have played a pivotal role in the elucidation of rare diseases. For myelodysplastic syndromes (MDS), they revealed the disease actually to be diverse rather than rare. Registry data enabled the definition of various MDS subtypes and prognostic scores tailoring therapy. These classifications have been revised and refined several times, and the differential diagnosis of MDS has become increasingly complex. At the same time, the diagnosis has been made more commonly and no longer by specialized centers of expertise only. Consequently, several registries have collected data with different focuses and from different patient subpopulations. The current review presents three MDS registries and their rationale, scope, design, and achievements. All three complement each other and will remain a mainstay to advance the knowledge on MDS as well as to validate the outcomes of clinical trials. However, delineation of subtypes after the most recent WHO and IPC revisions, as well as the determination of the newest risk score M of the International Prognostic Scoring System (IPSS-M), no longer just shift cut-offs but are based on multivariate compilations of highly specific genetic information. This paradigm shift involves challenging registries with respect to the assignment of all patients for whom this information has not yet been available.

References

Aul C, Gattermann N, Germing U, Runde V, Heyll A . [Myelodysplastic syndromes. The epidemiological and etiological aspects]. Dtsch Med Wochenschr. 1992; 117(33):1223-31. DOI: 10.1055/s-2008-1062434. View

Aul C, Germing U, Gattermann N, Minning H . Increasing incidence of myelodysplastic syndromes: real or fictitious?. Leuk Res. 1998; 22(1):93-100. DOI: 10.1016/s0145-2126(97)00089-1. View

Neukirchen J, Schoonen W, Strupp C, Gattermann N, Aul C, Haas R . Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. Leuk Res. 2011; 35(12):1591-6. DOI: 10.1016/j.leukres.2011.06.001. View

Bennett J, Catovsky D, Daniel M, Flandrin G, GALTON D, Gralnick H . Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982; 51(2):189-99. View

Nachtkamp K, Strupp C, Vukelja M, Kasprzak A, Haase D, Ganster C . The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification. Leukemia. 2024; 38(2):442-445. PMC: 10844089. DOI: 10.1038/s41375-024-02157-2. View

Germing U, Gattermann N, Strupp C, Aivado M, Aul C . Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res. 2000; 24(12):983-92. DOI: 10.1016/s0145-2126(00)00088-6. View

de Swart L, Smith A, Johnston T, Haase D, Droste J, Fenaux P . Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. Br J Haematol. 2015; 170(3):372-83. DOI: 10.1111/bjh.13450. View

Maassen A, Strupp C, Giagounidis A, Kuendgen A, Nachtkamp K, Hildebrandt B . Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts. Leuk Res. 2012; 37(1):64-70. DOI: 10.1016/j.leukres.2012.09.021. View

Germing U, Strupp C, Giagounidis A, Haas R, Gattermann N, Starke C . Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes. Leuk Res. 2012; 36(6):727-34. DOI: 10.1016/j.leukres.2012.02.014. View

10.

Strupp C, Nachtkamp K, Hildebrandt B, Giagounidis A, Haas R, Gattermann N . New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types. Leuk Res. 2017; 57:78-84. DOI: 10.1016/j.leukres.2017.02.008. View

11.

Khoury J, Solary E, Abla O, Akkari Y, Alaggio R, Apperley J . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022; 36(7):1703-1719. PMC: 9252913. DOI: 10.1038/s41375-022-01613-1. View

12.

Arber D, Orazi A, Hasserjian R, Borowitz M, Calvo K, Kvasnicka H . International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022; 140(11):1200-1228. PMC: 9479031. DOI: 10.1182/blood.2022015850. View

13.

de Swart L, Smith A, MacKenzie M, Symeonidis A, Neukirchen J, Mikulenkova D . Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance. Ann Hematol. 2017; 96(7):1105-1112. PMC: 5486793. DOI: 10.1007/s00277-017-3009-7. View

14.

Oster H, Crouch S, Smith A, Yu G, Shrkihe B, Baruch S . A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS. Blood Adv. 2021; 5(16):3066-3075. PMC: 8405190. DOI: 10.1182/bloodadvances.2020004055. View

15.

Schulz F, Nachtkamp K, Oster H, Mittelman M, Gattermann N, Schweier S . Validation of a novel algorithm with a high specificity in ruling out MDS. Int J Lab Hematol. 2024; 46(3):510-514. DOI: 10.1111/ijlh.14234. View

16.

Maschek H, Gutzmer R, Choritz H, Georgii A . Comparison of scoring systems in primary myelodysplastic syndromes. Ann Hematol. 1995; 70(6):301-8. DOI: 10.1007/BF01696616. View

17.

Greenberg P, Cox C, LeBeau M, Fenaux P, Morel P, Sanz G . International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079-88. View

18.

Greenberg P, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F . Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454-65. PMC: 4425443. DOI: 10.1182/blood-2012-03-420489. View

19.

Nachtkamp K, Stark R, Strupp C, Kundgen A, Giagounidis A, Aul C . Causes of death in 2877 patients with myelodysplastic syndromes. Ann Hematol. 2016; 95(6):937-44. DOI: 10.1007/s00277-016-2649-3. View

20.

Madry K, Lis K, Fenaux P, Bowen D, Symeonidis A, Mittelman M . Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry. Br J Haematol. 2022; 200(4):451-461. DOI: 10.1111/bjh.18542. View